To evaluate the long-term clinical utility of urinary ALCAM, HPX, and PRDX6, it is crucial to address these limitations, validate the results across diverse patient groups, and conduct additional studies to establish their specificity as biomarkers for SLE. This evidence concerns the gene ALCAM and systemic lupus erythematosus.